176 related articles for article (PubMed ID: 30319636)
1. Early Everolimus Initiation Fails to Counteract the Cytotoxic Response Mediated by CD8
Díaz-Molina B; Diaz-Bulnes P; Carvajal Palao R; Bernardo MJ; Rodriguez RM; Corte-Iglesias V; Moris de la Tassa C; Lambert JL; Suarez-Alvarez B
Front Immunol; 2018; 9():2181. PubMed ID: 30319636
[TBL] [Abstract][Full Text] [Related]
2. Suppressive effects of conversion from mycophenolate mofetil to everolimus for the development of cardiac allograft vasculopathy in maintenance of heart transplant recipients.
Watanabe T; Seguchi O; Nishimura K; Fujita T; Murata Y; Yanase M; Sato T; Sunami H; Nakajima S; Hisamatsu E; Sato T; Kuroda K; Hieda M; Wada K; Hata H; Ishibashi-Ueda H; Miyamoto Y; Fukushima N; Kobayashi J; Nakatani T
Int J Cardiol; 2016 Jan; 203():307-14. PubMed ID: 26523360
[TBL] [Abstract][Full Text] [Related]
3. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
Favi E; Citterio F; Spagnoletti G; Gargiulo A; Delreno F; Romagnoli J; Castagneto M
Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
[TBL] [Abstract][Full Text] [Related]
4. Terminal Ileac Ulcers Mimicked Post-transplantation Lymphoproliferative Disorder in a Heart Recipient Treated With Everolimus: A Case Report.
Iwasaki K; Seguchi O; Mochizuki H; Kimura Y; Toda K; Kumai Y; Kuroda K; Nakajima S; Watanabe T; Yanase M; Matsumoto Y; Fukushima S; Fujita T; Kobayashi J; Fukushima N
Transplant Proc; 2018 Dec; 50(10):4053-4056. PubMed ID: 30577313
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus/mycophenolate mofetil improved natural killer lymphocyte reconstitution one year after kidney transplant by reference to cyclosporine/azathioprine.
Vacher-Coponat H; Brunet C; Moal V; Loundou A; Bonnet E; Lyonnet L; Ravet S; Sampol-Manos E; Sampol J; Berland Y; George FD; Paul P
Transplantation; 2006 Aug; 82(4):558-66. PubMed ID: 16926601
[TBL] [Abstract][Full Text] [Related]
6. Everolimus-incorporated immunosuppressant strategy improves renal dysfunction while maintaining low rejection rates after heart transplantation in Japanese patients.
Imamura T; Kinugawa K; Ono M; Kagami Y; Endo M; Minatsuki S; Muraoka H; Kato N; Inaba T; Maki H; Hatano M; Yao A; Kyo S; Komuro I
Int Heart J; 2013; 54(4):222-7. PubMed ID: 23924935
[TBL] [Abstract][Full Text] [Related]
7. Rapidly progressive cardiac allograft vasculopathy in early onset regressed with everolimus treatment in an adult cardiac recipient.
Ishida J; Kinugawa K; Shiga T; Imamura T; Hatano M; Maki H; Inaba T; Yao A; Hirata Y; Nishimura T; Kyo S; Ono M; Nagai R
Int Heart J; 2012; 53(6):388-90. PubMed ID: 23258141
[TBL] [Abstract][Full Text] [Related]
8. Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients.
Arora S; Andreassen AK; Karason K; Gustafsson F; Eiskjær H; Bøtker HE; Rådegran G; Gude E; Ioanes D; Solbu D; Dellgren G; Ueland T; Aukrust P; Gullestad L;
Circ Heart Fail; 2018 Sep; 11(9):e004050. PubMed ID: 30354362
[TBL] [Abstract][Full Text] [Related]
9. Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine- or mycophenolate-treated patients.
Havenith SH; Yong SL; van Donselaar-van der Pant KA; van Lier RA; ten Berge IJ; Bemelman FJ
Transplantation; 2013 Jan; 95(1):184-91. PubMed ID: 23222818
[TBL] [Abstract][Full Text] [Related]
10. A 1-year randomized controlled study of everolimus versus mycophenolate mofetil with reduced-dose cyclosporine in maintenance heart transplant recipients.
Bara C; Dengler T; Hack MA; Ladenburger S; Lehmkuhl HB
Transplant Proc; 2013; 45(6):2387-92. PubMed ID: 23953553
[TBL] [Abstract][Full Text] [Related]
11. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients.
Lehmkuhl HB; Arizon J; Viganò M; Almenar L; Gerosa G; Maccherini M; Varnous S; Musumeci F; Hexham JM; Mange KC; Livi U;
Transplantation; 2009 Jul; 88(1):115-22. PubMed ID: 19584690
[TBL] [Abstract][Full Text] [Related]
12. The risk of polyomavirus-associated graft nephropathy is increased by a combined suppression of CD8 and CD4 cell-dependent immune effects.
Renner FC; Dietrich H; Bulut N; Celik D; Freitag E; Gaertner N; Karoui S; Mark J; Raatz C; Weimer R; Feustel A
Transplant Proc; 2013 May; 45(4):1608-10. PubMed ID: 23726630
[TBL] [Abstract][Full Text] [Related]
13. Pilot Conversion Study From Mycophenolate Mofetil to Everolimus in Stable ABO-Incompatible Kidney Transplant Recipients: Analysis of 1-Year Follow-Up Data.
Uchida J; Iwai T; Nishide S; Kabei K; Kuwabara N; Naganuma T; Kumada N; Takemoto Y; Nakatani T
Exp Clin Transplant; 2019 Apr; 17(2):190-195. PubMed ID: 30198840
[TBL] [Abstract][Full Text] [Related]
14. Plasma neutrophil gelatinase-associated lipocalin and worsening renal function during everolimus therapy after heart transplantation.
Imamura T; Kinugawa K; Doi K; Hatano M; Fujino T; Kinoshita O; Nawata K; Noiri E; Kyo S; Ono M
Int Heart J; 2015; 56(1):73-9. PubMed ID: 25742944
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
Spagnoletti G; Citterio F; Favi E; Rossi E; Delreno F; De Santis I; Salerno MP; Gargiulo A; Castagneto M
Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
[TBL] [Abstract][Full Text] [Related]
16. Modulation of natural killer (NK) receptors on NK (CD3-/CD56+), T (CD3+/CD56-) and NKT-like (CD3+/CD56+) cells after heart transplantation.
Aguilar P; Mathieu CP; Clerc G; Ethevenot G; Fajraoui M; Mattei S; Faure GC; Bene MC
J Heart Lung Transplant; 2006 Feb; 25(2):200-5. PubMed ID: 16446221
[TBL] [Abstract][Full Text] [Related]
17. Everolimus plus mycophenolate mofetil as initial immunosuppression in liver transplantation.
Jiménez-Pérez M; González Grande R; Rando Muñoz FJ; de la Cruz Lombardo J; Muñoz Suárez MA; Fernández Aguilar JL; Pérez Daga JA; Santoyo-Santoyo J; Manteca González R; Rodrigo López JM
Transplant Proc; 2015; 47(1):90-2. PubMed ID: 25645779
[TBL] [Abstract][Full Text] [Related]
18. Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: long-term follow-up of the SHIRAKISS randomized, prospective study.
Potena L; Prestinenzi P; Bianchi IG; Masetti M; Romani P; Magnani G; Fallani F; Coccolo F; Russo A; Ponticelli C; Rapezzi C; Grigioni F; Branzi A
J Heart Lung Transplant; 2012 Jun; 31(6):565-70. PubMed ID: 22341702
[TBL] [Abstract][Full Text] [Related]
19. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
[TBL] [Abstract][Full Text] [Related]
20. Immunological profiles of HIV-positive recipients of liver transplant.
Righi E; Ivaldi F; La Rosa A; Carnelutti A; Londero A; Bassetti M
Transpl Immunol; 2019 Dec; 57():101208. PubMed ID: 31102654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
